No Picture
News

Portal Biotechnologies and Multiply Labs Announce Partnership to Automate Cell Engineering In Cell Therapy Manufacturing

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate… … […]

News

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

Funding to support development of point-of-care diagnostic platform for women’s health CAMBRIDGE, Mass., May 21, 2024 /PRNewswire/ — Nanopath Inc., a point-of-care diagnostics company enabling high-quality molecular testing in minutes, announced today that it was awarded $4 million in… … […]

News

Sanofi, OpenAI, Formation Bio announce AI drug development partnership

French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the three companies announced Tuesday. The deal is the latest example of a tightening relationship between drugmakers and AI companies, and the second major deal that… … […]

[adinserter block="3"]
No Picture
News

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is… … […]

News

FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea

Published: May 21, 2024 By Tristan Manalac Pictured: FDA signage at its office in Maryland/iStock, hapabapa The FDA on Monday approved two biosimilars to Regeneron Pharmaceuticals’ blockbuster eye injection Eylea (aflibercept)—Biocon Biologics’ Yesafili (aflibercept-jbvf) and … […]

[adinserter block="3"]
No Picture
News

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also… … […]

[adinserter block="3"]
News

The 10 Most Common Issues Found During a Gas Safety Audit

Conducting a periodic gas safety audit is an important precautionary step for every life sciences facility and lab to undertake. During this audit, your gas provider should inspect all cylinders and tanks, manifolds, regulators, valves, visible piping, and more. This essential review can help ensure that your gas equipment is… … […]